Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics Plc (AKTX) is a clinical-stage biopharmaceutical company advancing innovative treatments for rare autoimmune and inflammatory diseases. This page provides investors and industry observers with timely updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.
Access comprehensive coverage of AKTX’s progress, including press releases on trial results, FDA designations, and partnership announcements. Our curated news collection focuses on developments related to coversin, nomacopan, and other pipeline candidates targeting complement-mediated disorders.
Key updates include progress in treating conditions like HSCT-TMA and Geographic Atrophy, manufacturing partnerships, and scientific presentations. All content is verified from primary sources to ensure accuracy for investment research and market analysis.
Bookmark this page for centralized access to AKTX’s latest developments in complement system therapeutics. Check regularly for objective updates on clinical advancements and corporate announcements relevant to biopharmaceutical investors.
Akari Therapeutics (Nasdaq: AKTX) has filed a provisional patent application with the USPTO for its novel antibody drug conjugate (ADC) platform utilizing the spliceosome payload PH1 for cancer treatment. The patent covers the platform's unique mechanism of modulating alternative splicing within cancer cells.
The technology targets cancer cells' ability to hijack alternative splicing (AS) processes, which affects tumor formation, growth, and metastasis. The PH1 payload demonstrates potential in disrupting cancer cell survival mechanisms across multiple types of cancers, including those resistant to current therapies.
The patent strengthens Akari's intellectual property portfolio and supports the development of their ADC programs, including AKTX-101 (Trop2 ADC with PH1 payload) and AKTX-102 (undisclosed target).
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on payload antibody drug conjugates (ADCs), will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.
CEO Abizer Gaslightwala will deliver a presentation and conduct one-on-one meetings with registered investors. The presentation will be available via video webcast starting September 5, 2025, at 7:00 AM ET for registered attendees and will remain accessible on the company's website for 90 days.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, will participate in the Virtual Investor Closing Bell Series on September 4, 2025 at 4:00 PM ET. During the event, CEO Abizer Gaslightwala will present a corporate overview focusing on the company's innovative payload platform for developing next-generation antibody drug conjugates (ADCs) in cancer treatment.
The event will feature a moderated discussion followed by a live Q&A session with investors. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days after the event.
Akari Therapeutics (Nasdaq: AKTX), a biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) for cancer treatment, has announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech virtual event.
The company's President and CEO, Abizer Gaslightwala, will present on Tuesday, August 19, 2025, at 2:00 PM ET. The event is part of a broader virtual conference running from August 19-21, 2025.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, has released a Virtual Investor "What This Means" segment featuring CEO Abizer Gaslightwala. The presentation focuses on the company's novel spliceosome modulator payload, PH1, which is being developed as part of their antibody drug conjugates (ADCs) platform for cancer treatment.
During the segment, Gaslightwala discussed ongoing research efforts to understand how the PH1 payload can disrupt key drivers of cancer cell growth, highlighting the company's commitment to advancing their oncology pipeline.
Akari Therapeutics (NASDAQ:AKTX) is advancing research on its novel antibody drug conjugate (ADC) payload PH1, a spliceosome modulator designed for cancer treatment. The company highlighted that PH1 demonstrates multiple mechanisms of action, including cancer cell death induction and immune system activation against tumors.
Key features of PH1 include its ability to target cancers driven by oncogenic factors like KRAS, BRAF, and FGFR3, reduced off-target toxicity through engineered linker technology, and resistance to standard efflux transporters. The company expects to release new preclinical data on PH1's impact against a key oncogenic driver before the end of 2025.
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs), announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
During the event, President and CEO Abizer Gaslightwala shared insights about his career journey, his commitment to the company, and his enthusiasm for Akari's development programs. The presentation is now accessible on-demand through virtualinvestorco.com and the company's investor relations website.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, has released a Virtual Investor segment discussing their recently granted India Patent No. 562,919. The patent, titled "Thailanstatin Analogs," covers the company's PH1 payload, proprietary cleavable and non-cleavable linkers, and ADC technology for cancer treatment applications.
The segment features CEO Abizer Gaslightwala explaining the significance of this patent protection for their immuno-oncology antibody drug conjugates (ADCs) technology platform.
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel payload antibody drug conjugates (ADCs), has released a "Meet the Team" video featuring Mark F. Kubik, their newly appointed Head of Business Development – Oncology. The video, which showcases Kubik, an industry leader known for his oncology expertise and successful transaction record leading to multiple approved therapeutic products, is now available on the company's website under the Investors section.
FAQ
What is the current stock price of Akari Therapeutics Plc (AKTX)?
What is the market cap of Akari Therapeutics Plc (AKTX)?
